

Preparing for the American Board
of Pathology (ABPath)
Examination of Fundamental
Knowledge and Skills

Hematopathology

Content Specifications



3 Overview:

4 Hematopathology Content Specifications

5
6 This guide outlines the content that may appear on the American Board of Pathology's
7 Hematopathology Subspecialty exam. It provides a framework based on the knowledge and skills
8 typically covered in Fellow-level training, along with applicable Core and Advanced Resident topics from
9 residency training that the trainee is expected to know or be able to perform.

10 **Key to Designations:**

11 C = Core/Foundational Knowledge

12 AR = Advanced Resident Knowledge

13 F = Fellow/Advanced Practitioner Knowledge

14 The exam assesses the knowledge, judgment, skills, and abilities necessary to identify specific entities,
15 properly process specimens, and diagnose and monitor diseases using methods common in the practice
16 of Hematopathology. The specific diseases, tests, and concepts listed in this document are important for
17 candidates to know, but it is not possible to create a fully comprehensive list of all the material needed
18 for certification and effective practice. Candidates should use this guide as a reference for preparing for
19 certification and professional practice.

20 Table of Contents

21 Contents

22 1. Testing in Hematology and Hematopathology	2
23 2. Normal Anatomy, Histology, Hematopoiesis and Hemostasis	3
24 3. Non-Neoplastic Disorders of Erythrocytes	3
25 4. Non-Neoplastic Disorders of Leucocytes	4
26 5. Multilineage Benign Hematopoietic Disorders	4
27 6. Infections with Manifestation in the Peripheral Blood	5
28 7. Benign Hematologic Disorders of the Bone Marrow Not Otherwise Classified	5
29 8. Benign Disorders of the Lymphoid Tissues	5
30 9. Fluid Specimens	5
31 10. Immunodeficiency Disorders	6
32 11. Hemostasis and Thrombosis	6
33 12. Myeloid Neoplasms	6
34 13. Acute Leukemias of Ambiguous Lineage	7

35	14. Lymphoid Neoplasms.....	7
36	15. Plasma Cell Neoplasms, Paraprotein Disorders, & Amyloidosis	8
37	16. Histiocytic/Dendritic Cell Neoplasms.....	8
38	17. Metastatic Neoplasms	8
39	18. Hematology & Hematopathology-Specific Administration & Laboratory Management.....	9

40

41

42

43 1. Testing in Hematology and Hematopathology

44	a. General Hematology Testing and Hematology Instruments	
45	i. General Consideration	C
46	ii. RBC Analysis	C
47	iii. WBC Analysis	C
48	iv. Platelet Analysis	C
49	b. Hemoglobinopathy Analysis	
50	i. Alkaline & Acid Electrophoresis	AR
51	ii. High Performance Liquid Chromatography (HPLC)	AR
52	iii. Capillary Electrophoresis	AR
53	iv. Isoelectric Focusing	AR
54	v. Advanced Hemoglobinopathy Analysis	F
55	c. Morphologic Methods	
56	i. Staining Methods	
57	1. Romanovsky Type Stains	C
58	2. Routine and Special Histologic Stains	C
59	3. Cytochemical and Advanced Hematology Stains	F
60	ii. Peripheral Blood Smear Review	C
61	iii. Fluid Review	C
62	iv. Bone Marrow Review	C
63	v. Review of Other Tissues in Hematopathology	C
64	d. Hemostasis and Thrombosis Testing	
65	i. Specimen Collection and Processing	C
66	ii. Coagulation and Fibrinolysis	AR
67	iii. Platelet Testing, including von Willebrand Disease	AR
68	iv. Thrombophilia Testing	AR
69	e. Immunohistochemistry	
70	i. Basic Methods	AR
71	ii. Pitfalls	AR
72	f. Flow Cytometry	
73	i. Basic Methodology	C
74	ii. PNH & Other Non-Neoplastic Disease Testing	C
75	iii. Lymphoid Testing	C
76	iv. Myeloid Testing	C
77	v. Advanced Flow Cytometry	F

78	g. Cytogenetic Testing	
79	i. Classical	AR
80	ii. FISH	AR
81	iii. Other Cytogenetic Techniques (e.g., aCGH, SNP)	AR
82	h. Molecular Testing	
83	i. Clonality/Lineage	AR
84	ii. Translocations/Mutations	AR
85	iii. Other Molecular Assays (e.g., Gene Expression Arrays)	AR
86	iv. Coagulation-Related Molecular Testing	AR
87		

88 2. Normal Anatomy, Histology, Hematopoiesis and Hemostasis

89	a. Erythrocytes (RBCs)	C
90	b. Leucocytes (WBCs)	C
91	i. Myeloid	C
92	1. Granulocytes	C
93	2. Monocytes/Dendritic Cells	C
94	3. Eosinophils/Basophils/Mast Cells	C
95	4. Other Myeloid Cells	C
96	ii. Lymphoid	C
97	1. B-Cells	C
98	2. T-Cells	C
99	3. NK-Cells	C
100	4. Other Lymphoid Cells	C
101	c. Plasma Cells	C
102	d. Normal Hemostasis & Thrombosis	C
103	i. Platelets & Megakaryocytes	C
104	ii. Coagulation and Fibrinolysis	C
105	e. General Hematopoiesis	C
106	f. Peripheral Blood	C
107	g. Bone Marrow	C
108	h. Lymph Nodes	C
109	i. Spleen	C
110	j. Thymus	C
111	k. Other Lymphoid Tissues (e.g., Tonsils)	C
112	l. Pediatric Issues, Including Fetal Hematopoiesis	AR
113		
114		

115 3. Non-Neoplastic Disorders of Erythrocytes

116	a. Anemias	
117	i. Iron Deficiency and Related Disorders	C
118	ii. Sideroblastic Anemias	
119	1. Acquired	AR
120	2. Inherited	F
121	iii. Erythrocyte Membrane Disorders	
122	1. Hereditary Spherocytosis	AR
123	2. Hereditary Elliptocytosis	AR
124	3. Other Erythrocyte Membrane Disorders (e.g., Spur Cell)	AR

125	iv.	Erythrocyte Enzyme Disorders	
126	1.	G6PD	AR
127	2.	Pyruvate Kinase Deficiency	AR
128	3.	Other Erythrocyte Enzyme Disorders	AR
129	v.	Other Hemolytic Anemias	
130	1.	Immune	C
131	2.	Non-Immune (e.g., Thermal Injury)	C
132	3.	Microangiopathic Hemolytic Anemia	C
133	vi.	Megaloblastic Anemias	C
134	vii.	Aplastic Anemias	C
135	viii.	Anemia Related to Chronic Disease & Other Disorders	C
136	ix.	Congenital Dyserythropoietic Anemia	F
137	x.	Hemoglobinopathies	
138	1.	Hb S and Related Disorders	C
139	2.	Hb C Disorders	AR
140	3.	Hb E Disorders	AR
141	4.	Other Hemoglobinopathies	F
142	xi.	Thalassemias	C
143	xii.	PNH	C
144	xiii.	Porphyrias	AR
145	xiv.	Other Causes of Anemia	
146	1.	Lead Poisoning	AR
147	2.	Diamond-Blackfan Anemia	F
148	b.	Erythrocytosis	AR
149	c.	Cold Agglutinin Disease	AR
150	d.	Advanced Erythrocyte Abnormalities	AR
151			
152			

4. Non-Neoplastic Disorders of Leucocytes

153	a.	Inherited Disorders with Morphologic Correlates	
154	i.	Pelger-Huet Anomaly	C
155	ii.	Alder-Reilly Anomaly	AR
156	iii.	Chediak-Higashi Syndrome	AR
157	b.	Neutrophils – Quantitative & Qualitative Aspects	C
158	c.	Monocytes – Quantitative & Qualitative Aspects	C
159	d.	Histiocytic Disorders	
160	i.	HLH/Macrophage Activation Disorders/Hemophagocytic Disorders	C
161	ii.	Storage Disorders	AR
162	iii.	Other Histiocytic Disorders (e.g., Prosthetic Associated Histiocyte Proliferation)	F
163	e.	Plasmacytoid Dendritic Cells	F
164	f.	Lymphocytes – Including Quantitative Aspects	C
165	g.	Eosinophils and Basophils	C
166	h.	Plasma Cells	C
167			
168			
169			

5. Multilineage Benign Hematopoietic Disorders

170	a.	Inherited Disorders (e.g., May-Hegglin Anomaly)	AR
-----	----	---	----

172	b. Other Benign Hematopoietic Disorders	F
173		
174	6. Infections with Manifestation in the Peripheral Blood	
175	a. Erythrocyte & Plasma Infections	
176	i. Malaria	C
177	ii. Babesia	C
178	iii. Other Erythrocyte & Plasma Infections	AR
179	b. Leucocyte Infections	
180	i. Infectious Mononucleosis	C
181	ii. Anaplasma & Ehrlichia	AR
182	iii. Other Infections of Leucocytes (e.g., Fungi including Histoplasma, Pertussis)	AR
183		
184		
185	7. Benign Hematologic Disorders of the Bone Marrow Not Otherwise Classified	
186	a. Infectious Disorders (e.g., Parvovirus)	C
187	b. Therapy Related Effects	AR
188	c. Bone Abnormalities	
189	i. Paget Disease	AR
190	ii. Renal Osteodystrophy	AR
191	d. Other Benign Disorders of Bone Marrow	F
192		
193	8. Benign Disorders of the Lymphoid Tissues	
194	a. Lymph Node	
195	i. Dermatopathic Lymphadenopathy	C
196	ii. Cat Scratch Disease	AR
197	iii. Toxoplasmosis	AR
198	iv. Infectious Mononucleosis	AR
199	v. Other Infectious Disorders	AR
200	vi. Kikuchi-Fujimoto Disease (i.e., Histiocytic Necrotizing Lymphadenitis)	AR
201	vii. Rosai-Dorfman Disease	AR
202	viii. Castleman Disease	AR
203	ix. Autoimmune Disorders	AR
204	x. Non-Lymphoid Inclusions (e.g., Mesothelial)	AR
205	xi. Syphilis	F
206	xii. Drug-Related (e.g., Phenytoin)	F
207	xiii. Other Benign Disorders of the Lymph Nodes	F
208	b. Spleen	
209	i. Lymphoid Hyperplasias	AR
210	ii. Splenic Cysts & Other Non-Neoplastic Proliferations (e.g., Hamartomas)	AR
211	c. Thymus	
212	i. Thymic Hyperplasia	AR
213	ii. Other Benign Thymus Disorders (e.g., Thymoma)	AR
214	d. Extranodal Lymphoid Tissue	AR
215		
216	9. Fluid Specimens	
217	a. CSF	C

218	b. Other Body Fluids	C
219		
220	10. Immunodeficiency Disorders	
221	a. Primary Immunodeficiencies	F
222	b. Secondary Immunodeficiencies	
223	i. Viral-Associated	F
224	ii. Iatrogenic	F
225	c. Immunodeficiency-Associated Lymphoproliferative Disorders	
226	i. HIV-Associated	AR
227	ii. PTLD	AR
228	iii. Other Iatrogenic Lymphoproliferative Disorders	F
229		
230	11. Hemostasis and Thrombosis	
231	a. Coagulation and Fibrinolytic Disorders	
232	i. Factor Deficiency or Functional Abnormalities	C
233	ii. Factor Inhibitors	AR
234	iii. Fibrinolysis	AR
235	b. Platelet Disorders and von Willebrand Disease	
236	i. Qualitative Issues with Normal Platelet Counts	C
237	ii. Thrombocytosis	C
238	iii. Thrombocytopenia	
239	1. Immune	C
240	2. Inherited	AR
241	3. Other Causes of Thrombocytopenia	AR
242	iv. von Willebrand Disease	C
243	v. Abnormal Platelet Morphology, Not Otherwise Specified	AR
244	c. Thrombophilic Disorders	
245	i. Heparin Induced Thrombocytopenia	C
246	ii. TTP/HUS	C
247	iii. DIC	C
248	iv. Laboratory Diagnosis of Thrombosis and Thrombophilia	AR
249	v. Fibrinolytic Thrombotic Disorders	AR
250	vi. Antiphospholipid Antibody Syndrome	AR
251	d. Antiplatelet and Anticoagulant Drugs	
252	i. Warfarin and Warfarin Monitoring	C
253	ii. Heparin and Heparinoid Monitoring	C
254	iii. Direct Thrombin and Factor Xa Inhibitor Monitoring	AR
255	iv. Antiplatelet Agent Monitoring	AR
256		
257	12. Myeloid Neoplasms	
258	a. Myeloproliferative Neoplasms	
259	i. CML (BCR-ABL1+)	C
260	ii. Polycythemia Vera	AR
261	iii. Primary Myelofibrosis	AR
262	iv. Essential Thrombocythemia	AR
263	v. Chronic Eosinophilic Leukemia, Not Otherwise Specified	AR
264	vi. Mastocytosis	AR

265	vii.	Other Myeloproliferative Neoplasms (e.g., CNL)	F
266	b.	Myeloid & Lymphoid Neoplasms with Eosinophilia and Gene Rearrangements	
267	i.	PDGFRA	AR
268	ii.	PDFGRB	AR
269	iii.	FGFR1	AR
270	iv.	PCM1-JAK2	AR
271	c.	Myelodysplastic/Myeloproliferative Neoplasms	
272	i.	CMML	C
273	ii.	Other MDS/MPN Disorders	AR
274	1.	Atypical CML	AR
275	2.	BCR-ABL1	AR
276	iii.	Juvenile Myelomonocytic Leukemia	
277	d.	Myelodysplastic Syndromes	AR
278	e.	AML and Related Precursor Neoplasms	
279	i.	AML with Recurrent Genetic Abnormalities	
280	1.	AML with t(8;21)	AR
281	2.	AML with inv(16) or t(16;16)	AR
282	3.	APL with t(15;17)	C
283	4.	AML with t(9;11)	F
284	5.	Other AML with Recurrent Genetic Abnormalities	F
285	ii.	AML with Myelodysplasia-Related Changes	AR
286	iii.	Therapy-Related Myeloid Neoplasms	AR
287	iv.	AML, Not Otherwise Specified	
288	1.	Acute Monoblastic/Monocytic Leukemia	AR
289	2.	Acute Erythroid Leukemia	F
290	3.	Acute Megakaryoblastic Leukemia	F
291	4.	Other AML, Not Otherwise Specified	F
292	v.	Myeloid Sarcoma	AR
293	vi.	Myeloid Proliferations with Germline Predisposition	F
294	1.	Myeloid Proliferations with Down Syndrome	AR
295	vii.	Blastic Plasmacytoid Dendritic Cell Neoplasm	AR
296	viii.	Other Myeloid Proliferations with Germline Predisposition	F
297			

13. Acute Leukemias of Ambiguous Lineage

F

14. Lymphoid Neoplasms

301	a.	B Lymphoblastic Leukemia/Lymphoma	
302	i.	B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified	AR
303	1.	B Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities	AR
304	ii.	Other B Lymphoblastic Leukemias & Lymphomas	F
305	b.	T Lymphoblastic Leukemia/Lymphoma	C
306	c.	Mature B-cell Neoplasms	
308	i.	CLL/SLL including Monoclonal B-cell Lymphocytosis	C
309	ii.	MALT Lymphoma	C
310	iii.	Follicular Lymphoma	C
311	iv.	Mantle cell Lymphoma	C

312	v.	Large cell Lymphomas	
313	1.	Diffuse Large B-cell Lymphoma, Not Otherwise Specified	C
314	2.	Primary Mediastinal Large B-cell Lymphoma	AR
315	3.	Other Large B-cell Lymphomas	F
316	vi.	Burkitt Lymphoma	C
317	vii.	Splenic Marginal Zone Lymphoma (SMZL)	AR
318	viii.	Hairy Cell Leukemia (HCL)	AR
319	ix.	Lymphoplasmacytic Lymphoma (LPL)	AR
320	x.	Nodal Marginal Zone Lymphoma (MZL)	AR
321	xi.	In situ Lymphoid Neoplasia	F
322	d.	Mature T- and NK-cell Neoplasms	
323	i.	T-cell and NK-cell LGL	C
324	ii.	Extranodal NK/T-cell Lymphoma, Nasal Type	C
325	iii.	Anaplastic Large Cell Lymphoma (ALK + and ALK -)	C
326	iv.	T-cell PLL	AR
327	v.	Adult T-cell Leukemia/Lymphoma	AR
328	vi.	Hepatosplenic T-cell Lymphoma	AR
329	vii.	Mycosis Fungoides & Sézary Syndrome	AR
330	viii.	PTCL, Not Otherwise Specified	AR
331	ix.	Angioimmunoblastic T-cell Lymphoma	AR
332	x.	Enteropathy-Associated T-cell Lymphoma and Other Intestinal T-cell Lymphomas	F
333	xi.	CD30+ Cutaneous Lymphoproliferative Disorders	F
334	xii.	Other Cutaneous T-cell Lymphomas	F
335	xiii.	Other Mature T- and NK-cell Neoplasms	F
337	e.	Hodgkin Lymphoma	
338	i.	Nodular Lymphocyte Predominant	C
339	ii.	Classic	C

341 15. Plasma Cell Neoplasms, Paraprotein Disorders, & Amyloidosis

- 342 a. Plasma cell Myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) C
- 343 b. Amyloidosis C
- 344 c. Cryoglobulinemia AR
- 345 d. POEMS (Polyneuropathy, Organomegaly, Endocrinopathy/Edema, Monoclonal Protein, and Skin Changes) AR

349 16. Histiocytic/Dendritic Cell Neoplasms

- 350 a. Landerhans cell Histiocytosis/Sarcoma AR
- 351 b. Follicular Dendritic Cell Sarcoma F
- 352 c. Histiocytic Sarcoma F
- 353 d. Other Histiocytic/Dendritic Neoplasms F

355 17. Metastatic Neoplasms

- 356 a. Metastases to the Bone Marrow C
- 357 b. Metastases to the Lymph Nodes C
- 358 c. Metastases to Other Lymphoid Tissue C

359

360 **18. Hematology & Hematopathology-Specific Administration & Laboratory Management**

- | | |
|---|---|
| 361 a. Hematology & Hematopathology Laboratory Management | F |
| 362 b. Rules and Regulations | F |
| 363 c. Laboratory Inspections | F |
| 364 d. QA/QC Issue | F |
| 365 e. Other Administration/Laboratory Management Issues | F |